19.06.19: Not intended for U.S. and UK Media

Regorafenib to be tested in brain cancer patients in multi-arm cooperation trialGBM AGILE, an international platform trial sponsored by the Global Coalition for Adaptive Research (GCAR) to evaluate multiple therapies for patients with newly diagnosed and recurrent glioblastoma, is now open for enrollment in the US with regorafenib as the first treatment arm / Results from the Phase II REGOMA study (Lombardi G et al, Lancet Oncol, 2018) support further evaluation of regorafenib in patients with newly diagnosed and recurrent glioblastoma, the most aggressive form of brain cancer / Medical need remains high in glioblastoma as treatment options are limited and patient outcomes have remained largely unchanged over several decadesmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news